Japan Tissue Engineering Co., Ltd. (7774) Stock Price

Japan Tissue Engineering is a company that operates regenerative medicine-based businesses, aiming for fundamental treatment through tissue regeneration. The company has adopted the vision of "making regenerative medicine ordinary medical care" and operates three business segments: regenerative medicine product business (developing, manufacturing, and selling regenerative medicine products), regenerative medicine contract business (undertaking development and manufacturing services related to regenerative medicine), and research and development support business (developing, manufacturing, and selling human cultured tissues for research purposes).

The company became part of the Teijin Group in 2021 and has expanded its business through cooperation with its parent company, Teijin Corporation. Additionally, it collaborates with Teijin Regenerate Corporation, established in 2023, in the regenerative medicine CDMO business. Japan Tissue Engineering's core competency lies in tissue engineering technology, providing technology to regenerate tissues and organs by utilizing cell culture and biomaterial engineering.

In the regenerative medicine product business, the company has developed products including autologous cultured epidermis JACE, autologous cultured cartilage JACC, autologous cultured corneal epithelium NEPIC, autologous cultured oral mucosal epithelium OCULAR, and melanocyte-containing autologous cultured epidermis JASMINE, which are provided to medical institutions. These products aim to restore tissue and organ function by culturing and transplanting cells from patients themselves.

In the regenerative medicine contract business, the company provides CDMO (contract development and manufacturing organization) services and CRO (contract research organization) services to academia, medical institutions, and companies. This enables comprehensive support from the seed development stage through commercialization, regardless of cell type or product format.

In the research and development support business, the company develops, manufactures, and sells the LabCyte series of human cultured tissues for research purposes, utilizing tissue engineering technology. LabCyte offers three product lines: "Epi-Model," "Corneal Model," and "Epi-Kit," which are used to confirm safety and efficacy in pharmaceutical and cosmetic development.

In new pipeline development, the company is working on allogeneic cultured epidermis and CAR-T cell therapy development. Allogeneic cultured epidermis is a product made from other individuals' skin, aimed at industrializing regenerative medicine. CAR-T cell therapy targets acute lymphoblastic leukemia and is being developed in cooperation with Nagoya University.

Japan Tissue Engineering operates businesses based on regenerative medicine, aiming to achieve fundamental treatment through tissue regeneration. The company has adopted the vision of "making regenerative medicine a standard medical treatment." It operates three business segments: regenerative medicine product business (developing, manufacturing, and selling regenerative medicine products), regenerative medicine contract business (undertaking development and manufacturing services related to regenerative medicine), and research and development support business (developing, manufacturing, and selling human cultured tissues for research).

The company's growth strategy is divided into three pillars: strengthening the foundation, expanding the market, and expanding into new domains. In strengthening the foundation, the company aims to leverage expertise gained from regenerative medicine product offerings to maximize sales and profits from existing businesses and establish a profitable operational base. In market expansion, the company targets markets with larger patient populations different from existing products, pursuing significant sales growth through new autologous product launches and expanded indications.

In domain expansion, the company aims to realize expansion into new products and domains such as allogeneic products and cancer immunotherapy, targeting medium-term goals of 50 billion yen in sales and operating profit margin exceeding 10%. Specifically, the company plans to launch cultured epidermis using allogeneic cells in the dermatology domain and autologous CAR-T cell therapy in development with Nagoya University.

Japan Tissue Engineering is guided by the management philosophy of becoming a company valued by society through the industrialization of regenerative medicine. Under strict compliance with laws and ethics, the company aims to contribute to improving patients' quality of life. Through this commitment, the company believes all stakeholders can live better lives.